Advertisements

Tissue Engineering Market Insights

The tissue engineering market is projected to reach USD 8.9 billion by 2028 from an estimated USD 4.4 billion in 2023, at a CAGR of 15.3%

Table Of Contents

Tissue Engineering Market in terms of revenue was estimated to be worth $4.4 billion in 2023 and is poised to reach $8.9 billion by 2028, growing at a CAGR of 15.3% from 2023 to 2028 according to a new report by MarketsandMarkets™.

The growing demand for innovative tissue engineering solutions for the treatment of chronic diseases and for repair and regeneration of tissues and technological developments such as 3D bioprinting is promoting the growth of the tissue engineering market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34135173

Based on product type, the tissue engineering market has been segmented into scaffolds, tissue grafts, and other products. Tissue grafts are further categorized into allografts, autografts, xenografts, and synthetic grafts. In 2022, the scaffold segment accounted for the largest share of the tissue engineering market. Increasing research activities for the development of advanced solutions for the repair and reconstruction of damaged tissues and organs is driving the demand for scaffolds.

Based on material, the tissue engineering market has been differentiated into synthetic material and biologically derived material. The synthetic material segment holds a major market share and is expected to grow at a higher rate during the forecast period 2023-2028. This can be attributed to increasing demand for cost effective and advanced treatment solutions for tissue repair and regeneration. In addition, the increasing adoption of innovative cell therapies is promoting segment growth in the tissue engineering market.

By application, the tissue engineering market has been further categorized as cardiovascular diseases, dermatology & wound care, orthopedics & musculoskeletal disorders, dental disorders, and others. Orthopedics & musculoskeletal disorders accounted for the major market share of the tissue engineering market in 2022. The large share of this segment can be attributed to the increasing demand for high-quality advanced solutions for the treatment of bone diseases. The rising adoption of tissue engineering solutions for bone regeneration and tissue reconstruction is promoting the growth of the orthopedics & musculoskeletal disorders segment in the tissue engineering market.

Based on end users, the tissue engineering market has been categorized into hospitals, specialty centers and clinics, and ambulatory surgical centers. The ambulatory surgical centers segment is expected to grow at a higher rate during the forecast period 2023-2028. Ambulatory surgical centers are also known as same-day surgery centers. The growing adoption of advanced surgical technologies and the rising need for less time-consuming surgical processes is promoting the growth of the ambulatory surgical centers segment in the tissue engineering market.

The tissue engineering market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The rising research activities and technological advancements in the medical sector in the North American region are the major driving factors for the growth of the tissue engineering market. Additionally, increasing investments and funding for the development of innovative cell therapies for the treatment of degenerative diseases is promoting the growth of the tissue engineering market in the North America region.

Key Market Players of Tissue Engineering Industry:

Key players in the tissue engineering market include Organogenesis (US), AbbVie Inc. (US), Baxter (US), BD (US), B. Braun (Germany), TEIJIN Limited (Japan), Institut Straumann AG (Switzerland), Integra Lifesciences (US), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), NuVasive, Inc. (US), Stryker (US), Terumo Corporation (Japan), W. L. Gore & Associates Inc. (US), Zimmer Biomet (US), Smith & Nephew plc (UK), MIMEDX Group, Inc. (US), BioTissue (US), CollPlant Biotechnologies Ltd. (Israel), Sumitomo Pharma Co., Ltd. (Japan), Matricel GmbH (Germany), Mallinckrodt (US), Regrow Biosciences Pvt Ltd (India), Vericel Corporation (US), Tecnoss S.R.L. (Italy), Tegoscience (South Korea), and Tissue Regenix (UK).

healthcaremedical

Leave a Reply

    © 2024 Crivva - Business Promotion. All rights reserved.